Skip to content
OpenCapital
Get started

Zymeworks ZYME Cash & Equivalents

Cash & Equivalents at other companies

Pfizer logo
PfizerPFE
$1.76B+18.8%
Amgen logo
AmgenAMGN
$559M+10.0%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$248.47M+152%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$102.06M-44.6%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$176.35M+51.7%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$155.66M-43.4%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's cash & equivalents?
Zymeworks (ZYME) reported cash & equivalents of $244.28M in Q1 2026.
How has Zymeworks's cash & equivalents changed year-over-year?
Zymeworks's cash & equivalents increased by 220.6% year-over-year, from $76.2M to $244.28M.
What is the long-term trend for Zymeworks's cash & equivalents?
Over 5 years (2020 to 2025), Zymeworks's cash & equivalents has grown at a -29.8% compound annual growth rate (CAGR), from $242.04M to $41.16M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.